GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (FRA:S09) » Definitions » EV-to-EBITDA

Sutro Biopharma (FRA:S09) EV-to-EBITDA : 1.57 (As of Sep. 24, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sutro Biopharma's enterprise value is €-94.3 Mil. Sutro Biopharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was €-60.0 Mil. Therefore, Sutro Biopharma's EV-to-EBITDA for today is 1.57.

The historical rank and industry rank for Sutro Biopharma's EV-to-EBITDA or its related term are showing as below:

FRA:S09' s EV-to-EBITDA Range Over the Past 10 Years
Min: -32.27   Med: -1.76   Max: 25.37
Current: 1.64

During the past 8 years, the highest EV-to-EBITDA of Sutro Biopharma was 25.37. The lowest was -32.27. And the median was -1.76.

FRA:S09's EV-to-EBITDA is ranked better than
62.91% of 461 companies
in the Biotechnology industry
Industry Median: 8.7 vs FRA:S09: 1.64

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-24), Sutro Biopharma's stock price is €3.34. Sutro Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-1.704. Therefore, Sutro Biopharma's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Sutro Biopharma EV-to-EBITDA Historical Data

The historical data trend for Sutro Biopharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma EV-to-EBITDA Chart

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -3.13 -27.35 -5.63 -1.68 1.38

Sutro Biopharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.53 0.71 1.38 -1.13 2.50

Competitive Comparison of Sutro Biopharma's EV-to-EBITDA

For the Biotechnology subindustry, Sutro Biopharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sutro Biopharma's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's EV-to-EBITDA falls into.



Sutro Biopharma EV-to-EBITDA Calculation

Sutro Biopharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-94.282/-59.95
=1.57

Sutro Biopharma's current Enterprise Value is €-94.3 Mil.
Sutro Biopharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-60.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sutro Biopharma  (FRA:S09) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Sutro Biopharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.34/-1.704
=At Loss

Sutro Biopharma's share price for today is €3.34.
Sutro Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.704.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Sutro Biopharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sutro Biopharma Business Description

Traded in Other Exchanges
Address
111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Sutro Biopharma Headlines

No Headlines